Viewing nowOlmesartan Medoxomil 20 mg Tablet
Olmesartan Medoxomil 20mg
Tablet · Prescription medication
Daehwa Pharmaceutical Co., Ltd.

MFDS item code 201100901 · Approved 2011.02.24 · Insurance code 645603980
Treatment of essential hypertension
Essential hypertension refers to a condition where blood pressure remains consistently high without a specific cause. This medication is used to control essential hypertension, stabilize blood pressure, and prevent cardiovascular complications.
<Adults> The recommended initial dose is 10mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, increase the dose to 20mg once daily. If further blood pressure reduction is required, the dose may be increased to a maximum of 40mg once daily. The antihypertensive effect appears within 2 weeks after starting treatment and reaches its maximum after approximately 8 weeks. If blood pressure is not controlled with this medicine alone, it may be coadministered with a thiazide diuretic, such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). In patients who may have intravascular volume depletion (e.g., patients receiving diuretics, especially those with renal impairment), it is recommended that treatment be initiated at a low dose while their condition is monitored carefully. <Elderly patients> No dose adjustment is required when this medicine is administered to patients aged 65 years or older. Although no overall differences in efficacy and safety have been observed between elderly and younger patients, a more sensitive response in some elderly patients cannot be ruled out. <Patients with renal impairment> The maximum dose for patients with mild to moderate renal impairment (creatinine clearance 20-60mL/min) is 20mg once daily. <Patients with hepatic impairment> No dose adjustment is required for patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, which may be increased to a maximum of 20mg daily. Since there is no experience with use in patients with severe hepatic impairment, administration of this medicine is not recommended.
<Children> The safety and efficacy in children have not been established.
This medication can cause severe harm or death to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it must be discontinued immediately upon confirmation of pregnancy. Individuals allergic to certain ingredients, those who are pregnant or breastfeeding, patients undergoing kidney dialysis, those with severe liver impairment, patients with bile duct obstruction, and individuals with genetic problems such as lactose intolerance should not take this medication. Patients with reduced blood volume or salt, those with impaired kidney function, renal artery hypertension patients, those at risk of hyperkalemia, and individuals with certain heart conditions should be particularly cautious when taking this medication, and blood pressure or kidney function should be monitored regularly. During the treatment, dizziness may occur, and it is advisable to avoid dangerous activities such as heavy lifting or driving. In clinical trials, this medication has been generally safe, with the most common side effect reported being dizziness; rare side effects include chest pain, swelling, indigestion, headache, and skin rash. If chronic diarrhea or weight loss occurs, it may be necessary to discontinue this medication due to the potential for intestinal disease. Interactions may occur when taken with potassium-sparing diuretics or potassium supplements, certain antihypertensives, lithium, and non-steroidal anti-inflammatory drugs, so consulting a physician is recommended. Due to the severe risk of fetal harm, this medication should be discontinued immediately upon confirmation of pregnancy, and if breastfeeding, consideration should be given to discontinuing either the medication or breastfeeding, as abnormal reactions may occur in infants. The safety and efficacy in children have not been sufficiently established, and elderly patients may have different metabolic capacities, so caution is warranted. In the event of overdose, symptoms such as hypotension or palpitations may occur, and appropriate treatment should be provided if necessary. This medication is known to have a low risk of carcinogenicity or genotoxicity, but if any unusual symptoms appear during use, immediate consultation with healthcare professionals is advised.
Dizziness, chest pain, peripheral edema, vertigo, abdominal pain, dyspepsia, gastroenteritis, nausea, palpitations, hypercholesterolemia, hyperlipidemia, hyperuricemia, arthralgia, arthritis, myalgia, rash, facial edema, asthenia, angioedema, anaphylaxis, vomiting, chronic malabsorption syndrome - similar bowel diseases, intestinal vascular edema, rhabdomyolysis, hyperkalemia, acute renal failure, increased serum creatinine, hair loss, pruritus, urticaria, autoimmune hepatitis, headache, hypertension, epistaxis, upper respiratory infection, asthma, cough
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air and moisture. It is preferable to maintain the storage temperature between 1 and 25 degrees Celsius to preserve its effectiveness for a long time.
White round film-coated tablet
30 tablets/box [(10 tablets/blister x 3)], 30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowOlmesartan Medoxomil 20mg
Tablet · Prescription medication
Daehwa Pharmaceutical Co., Ltd.

Olmesartan Medoxomil 20mg
Tablet · Prescription medication
Daewoong Pharmaceutical Co., Ltd.

Olmesartan Medoxomil 10mg
Tablet · Prescription medication
Daewoong Pharmaceutical Co., Ltd.

Olmesartan Medoxomil 40mg
Tablet · Prescription medication
Daewoong Pharmaceutical Co., Ltd.

Olmesartan Medoxomil 10mg
Tablet · Prescription medication
Hana Pharmaceutical Co., Ltd.

Olmesartan Medoxomil 10mg
Tablet · Prescription medication
Jongkeundang Co., Ltd.

Olmesartan Medoxomil 20mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

Olmesartan Medoxomil 20mg
Tablet · Prescription medication
Jinyang Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.